A clinical analysis of a patient with a rare form of secondary facial pain (Herzenberg's disease) is presented. The conducted research and pharmacological tests made it possible to exclude such diseases as trigeminal neuralgia, stylohyoid syndrome, TMJ pain dysfunction, dental plexalgia, myofascial facial pain syndrome. The patient is consulted by a dental surgeon to exclude pathology of the parotid salivary gland and sialolithiasis. The patient was treated with broad-spectrum antibiotics for 8 days. Also, supportive therapy was prescribed: desensitizing, vitamins, as well as an anxiolytic and an antidepressant in minimum therapeutic doses for a course of 14 days (with subsequent correction of the dosage and duration of administration) to correct the emotional state of the patient. We recommend a gentle diet (alkaline warm drink, soft food), and a diet that does not provoke salivation. Locally it was recommended to rinse with antimicrobial drugs, phonophoresis, electrophoresis, magnetotherapy. On the 6th day of therapy, the therapeutic effect was obtained. By the 14th day of therapy, the pain syndrome was leveled.

Authors present a case-report of a 36-year-old patient with pain syndrome in the face region (craniomandibular dysfunction with occlusive disorders) involving pericranial muscles and shoulder girdle muscles. Thioctic acid was prescribed as a basic therapy, and relaxation tire, mimic gymnastics, post-isometric relaxation, vitamin and mineral complex were additionally used. Thioctic acid was prescribed according to the following scheme: stage I - intravenous injections of thioctic acid (600 mg/daily, 5 procedures, every other day); stage II - oral administration of the drug in the dose of 600 mg/daily for 3 months. A significant reduction of pain syndrome and the palpable tension of muscles were noted; the symmetric even muscle tone was revealed. This case-report demonstrates the high efficacy of thioctic acid in treatment of patients with craniomandibular disorders using the 2-stage scheme. There was a significant improvement of quality of life of the patients due to the additional use of vitamin and mineral complex and medical tools (relaxation tire) for treatment at all stages of pain formation.

OBJECTIVE:To study the efficacy and safety of tenoten in the preventive treatment of frequent episodic tension-type headache (FETHA) compared to patients treated with pain relievers.MATERIAL AND METHODS:A study included 60 patients with FETHA. Patients of the main group (n=30) received tenoten in addition to standard treatment. The study comprised 3 visits: beginning of treatment, after one month and after three months. All patients underwent physical and clinical/neurological examinations. In each visit, treatment efficacy was assessed according the following parameters: VAS scores (0-10) for assessment of pain and tension in pericranial muscles in 6 standard points, mean frequency and duration of the headache episode, quality of life indices, Beck depression scores, Spilberger trait and state anxiety, autonomic symptom severity, parameters of sleep disorders, frequency of adverse effects, CGI scores (0-7).RESULTS AND CONCLUSION:Tenoten as a preventive medication reduced the frequency of headache episodes that allowed to diagnose patients with rare episodic tension-type headache in the end of treatment. At the same time, there was a significant reduction in headache intensity during the episode and decrease in amount of analgesics used by the patients.

Panic disorder is a widespread socially significant disease which genetic nature is poorly known. Since panic-driving features of cholecystokinin had been discovered, the gene that encodes this polypeptide (CCK ) and its receptors (CCKAR, CCKBR), as well as the mutations within, have been extensively studied. The aim of the present research was to assess frequencies of occurrence of seven single nucleotide substitutions in genes CCK, CCKAR, and CCKBR in the sample of patients with diagnosed panic disorder, and in the control sample of unexamined Moscow citizens. Reliable increase in occurrence frequency of rs1805000:T single nucleotide substitution in CCKBR gene was eventually found in the sample of panic disorder patients compared to the control, which allow us to suspect the involvement of this SNP into panic disorder aetiology. We also found the association of allele combination CCK rs11571842:A + CCKAR rs1800908:T with panic disorder development.

The dopaminergic system plays a major role in migraine. Dopamine beta hydroxylase (DBH) is responsible for maintaining dopamine-to-norepinephrine ratio implicated in migraine pathophysiology. We aimed to look for association of polymorphisms in dopaminergic genes in genetic susceptibility to migraine in Russian population. In the present study DBH polymorphisms rs1611115 was selected. The aim of this study was to determine whether the polymorphisms rs1611115 in DBH gene influenced any particular symptoms of the disease.

Background: Cholecystokinin (CCK) is one of the most abundant neurotransmitter peptides in the brain. CCK coexists with dopamine in dopaminergic neurons, and modulates the release of dopamine in the nucleus accumbens. The CCK system is believed to be involved in pain processing. The aim of the study was to investigate the prevalence of -81A/G (rs1799723), -128G/T (rs1800908) and 984T/C (rs1800857) polymorphisms of the CCK-AR gene in migraine patients and controls.

The objective of the investigation was to study the clinical efficacy, tolerability, and side effects of adepress in patients with mild and moderate anxiety-depressive disorders and psychoautonomic syndrome. The investigation included 30 outpatients, of whom 29 completed it. Monotherapy with adepress (paroxetine) was used in a dose of 10—20 mg/day for 8 weeks. Adverse reactions were observed in one-third of the patients within the first 2 weeks of therapy. Their intensity was not more than 3 visual analog scale scores. They required neither dose adjustment nor drug discontinuation and ceased spontaneously. After 8 weeks, the positive effect of the therapy was noted in all the patients. Adepress was found to show a high clinical efficacy and antidepressant, anxiolytic, and autonomic stabilizing activities. Adepress also normalized the sleep-wake cycle and diminished tension headache.

Panic disorder is a common, socially important human neurological disease. It is known that this disease has a strong genetic basis. Many laboratories investigate candidate genes involved in the control of pathological anxiety. This review summarizes the results of these studies and testify that the development of a panic disorder is associated with the polymorphism of the genes of key neurotransmitter systems of the brain (serotonin, dopamine, cholecystokinin), as well as their metabolizing enzymes. Based on the available data, a complex approach is suggested to enable the identification a genotype that provides predisposition to panic disorder.

The objective of the investigation was to study the clinical efficacy, tolerability, and side effects of adepress in patients with mild and moderate anxiety-depressive disorders and psychoautonomic syndrome. The investigation included 30 outpatients, of whom 29 completed it. Monotherapy with adepress (paroxetine) was used in a dose of 10—20 mg/day for 8 weeks. Adverse reactions were observed in one-third of the patients within the first 2 weeks of therapy. Their intensity was not more than 3 visual analog scale scores. They required neither dose adjustment nor drug discontinuation and ceased spontaneously. After 8 weeks, the positive effect of the therapy was noted in all the patients. Adepress was found to show a high clinical efficacy and antidepressant, anxiolytic, and autonomic stabilizing activities. Adepress also normalized the sleep-wake cycle and diminished tension headache.